Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy
Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy
Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC
EAU 2024: Bladder cancer latest
Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
ASCO GU 2024: Latest in PARP inhibitors for prostate cancer
Updates on lung cancer from WCLC and ESMO 2023
Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC
Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC